QGEN vs TMO: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
TMO is the larger of the two ($249.73B market cap): the incumbent the market prices for continued execution (24.26x forward earnings, beta 0.85). QGEN is the smaller challenger ($10.22B), cheaper on forward earnings (18.54x): more room to run, but more to prove. If you believe TMO earns its premium (24.26x forward earnings, so the market expects more from it), TMO fits. If you believe in paying less for profit, QGEN fits at 18.54x.
QGEN vs TMO: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | QGEN | TMO | What it tells you |
|---|---|---|---|
| Market cap | $10.22B | $249.73B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 18.54 | 24.26 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 26.75 | 35.55 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.56 | 0.85 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 67% of range | 82% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.94 | 4.56 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: QGEN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how QGEN and TMO affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. QGEN and TMO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined QGEN and TMO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does QIAGEN (QGEN) do?
QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat-Dx (syndromic infectious-disease testing), QuantiFERON (latent tuberculosis detection), and QIAcuity digital PCR. It serves more than 500,000 customers across molecular diagnostics, applied testing, academic research, and pharma, with a portfolio of 500-plus proprietary consumables and automated workflows. The December 2025 acquisition of Parse Biosciences pushed its Sample technologies franchise into single-cell analysis, one of five strategic growth pillars the company is steering toward its 2028 goals.
What does Thermo Fisher Scientific (TMO) do?
Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. The company operates through four reportable segments: Life Sciences Solutions (reagents, proteins, and consumables for research and bioproduction), Analytical Instruments (mass spectrometers, chromatography systems, electron microscopes, and laboratory equipment), Specialty Diagnostics (clinical diagnostic kits and transplant diagnostics), and Laboratory Products and Biopharma Services (supply-chain distribution, contract research through PPD, and contract drug manufacturing through Patheon). Revenue is generated through instrument sales, high-margin consumables and reagents that customers repurchase continuously, long-term service contracts, and growing contract development and manufacturing (CDMO) fees; consumables and services collectively account for a majority of annual sales and provide durable recurring revenue.
QGEN vs TMO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- QGEN drivers: QIAstat-Dx syndromic testing; Sample technologies and single-cell.
- TMO drivers: Bioprocessing and Biologic Drug Manufacturing Tailwind; Recurring Consumables and Reagents Engine.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. For TMO, the most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth.
QGEN or TMO: which should you pick?
If the story you believe is QGEN's (QIAstat-Dx syndromic testing), QGEN is the more direct way to own it; if it is TMO's (Bioprocessing and Biologic Drug Manufacturing Tailwind), TMO is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the QGEN and TMO guides.
QGEN vs TMO: the full fundamentals
QGEN. At ~$10.2 billion and ~19x forward earnings, QGEN is valued as a steady compounder: consensus has 2026 adjusted EPS at ~$2.49 on ~$2.14 billion of sales, rising to ~$2.67 in 2027 on ~7% revenue growth. The stock has re-rated since mid-2026 (up ~13% over three months and ~9% in 2026) after two quarterly beats and the Barclays upgrade, and analysts' average target of ~$49.77 now sits almost exactly at the ~$49.46 price. The valuation reflects durable consumable revenue and margin discipline against low-single-digit organic growth.
TMO. Thermo Fisher trades at roughly 24 times forward earnings and ~36 times trailing GAAP earnings, which include heavy acquisition amortization, after a third quarter that beat on EPS for the fourth time running. Analysts expect 2026 adjusted EPS of ~$25.28 on ~$48.0 billion of revenue and ~$27.79 on ~$50.5 billion in 2027, roughly 10% growth each year, and the ~$757 mean target from 25 analysts sits about 12% above the November 20 price. Trailing free cash flow of ~$6.4 billion still gives the company flexibility for repurchases, dividends and acquisitions.
Headline figures (approximate, November 2026): QGEN shows revenue (ttm) ~$2.1B (sales growth ~2.9% YoY in Q3 2026), latest quarter (q3 2026) Sales ~$548M (+2.9% YoY); adjusted EPS $0.65 vs ~$0.63 expected, margins (gross / operating, ttm) ~67% / ~27%, net income (ttm) ~$385M; TMO shows revenue (ttm) ~$47.4 billion; full year 2025 ~$44.6 billion, q3 2026 revenue ~$12.14 billion, up ~9% year over year, q3 2026 adjusted eps ~$6.68 vs ~$6.40 expected, margins (ttm) Gross ~41%, GAAP operating ~19%, net ~15%.
The bottom line: QGEN vs TMO
QGEN and TMO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined QGEN and TMO exposure against your real portfolio. It is not an investment adviser.
Wondering how QGEN or TMO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about QIAGEN
Ask Walnut's AI anything about QGEN and see how it fits what you own.
FAQ
What is the difference between QGEN and TMO?
+
QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat-Dx (syndromic infectious-disease testing), QuantiFERON (latent tuberculosis detection), and QIAcuity digital PCR. Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is QGEN or TMO the better stock?
+
Neither is universally better. TMO is the larger incumbent; QGEN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, QGEN or TMO?
+
On forward P/E (as of November 2026), QGEN trades at 18.54x and TMO at 24.26x, so QGEN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both QGEN and TMO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of QGEN vs TMO?
+
QGEN: QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. A large share of revenue tracks academic, pharma, and life-sciences research budgets, which softened in the U.S. and remain sensitive to funding cycles. Roughly half of sales are outside the U.S., so currency moves materially affect reported results (reported growth outpaced constant-currency growth in Q1 2026). QIAGEN competes against much larger, better-capitalized rivals, and guidance cuts have shown the top line is vulnerable to demand shocks: even after a firmer September quarter, sales grew only ~2.9% year over year, and consensus for 2027 is ~7% revenue growth. Net debt is real (~$1.65 billion of debt against ~$833 million of cash), though manageable against ~$751 million of trailing EBITDA. QIAGEN itself has flagged new pressures on global tuberculosis programs, which matter directly to QuantiFERON demand. A change of CEO, with Jonathan M. Pratt succeeding Thierry Bernard, can bring shifts in strategy or priorities, and integration of acquisitions like Parse Biosciences carries execution risk. TMO: The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. Thermo Fisher's active acquisition strategy carries integration and leverage risk, particularly after committing approximately $13 billion to mergers and acquisitions in 2025 alone; total debt stood near ~$41.4 billion against ~$6.1 billion of cash on the September 2026 balance sheet, and a large deal that underperforms expectations could weigh on earnings and the balance sheet simultaneously. Geopolitical friction, particularly regarding China, creates both a demand risk (softer orders from Chinese academic and industrial customers) and a supply chain risk, while tariff policy changes can disrupt cost structures. Finally, valuation risk remains: the stock trades near ~36 times trailing GAAP earnings and ~24 times forward estimates, so a slip in growth from the third quarter's ~9% pace would test a multiple that has already expanded this year.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell QGEN or TMO; figures are approximate and dated (as of November 2026). Verify current data before investing.